GlassScriptPhysician profile
Roberto Gomez-Suarez
NPI 1952503674
$1,606.41
in general payments reported to CMS, 2019-2025
14 companies · $175 in 2025
The $175 reported for 2025 was less than what a typical Pediatric Gastroenterology provider received nationally (typical 2025 total: $195).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $188 · 2020: $45.05 · 2021: $147 · 2022: $370 · 2023: $345 · 2024: $338 · 2025: $175.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $835 · Education: $22.16.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $834.93 |
| Education | $22.16 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Coloplast Corp | $542.66 | 2022-2025 | Peristeen, Speedicath |
| Abbvie INC. | $371.61 | 2019-2023 | |
| Regeneron Healthcare Solutions, INC. | $148.66 | 2023-2024 | Dupixent |
| Albireo Pharma, INC. | $126.50 | 2022 | |
| Medtronic, INC. | $124.85 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $86.29 | 2021-2025 | Gattex, Eohilia |
| Dentsply Ih Ab | $42.39 | 2025 | Navina Rectal Catheter Set Regular |
| Neuraxis, INC. | $35.48 | 2022 | |
| Mirum Pharmaceuticals, INC. | $32.26 | 2025 | Livmarli |
| Janssen Biotech, INC. | $23.26 | 2025 | Tremfya |
| Boehringer Ingelheim Pharmaceuticals, INC. | $20.74 | 2024 | Cyltezo |
| Regeneron Pharmaceuticals, INC. | $19.53 | 2024 | Dupixent |
| Travere Therapeutics, INC. | $17.50 | 2019 | |
| Qol Medical, LLC | $14.68 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Roberto Gomez-Suarez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.